🌱 KidneyEnergy.com

← brief for 2026-08-19 · Slowing decline

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease

Trial B Not peer reviewed Small trial

Key takeaways

This first-in-human study will test the safety and drug levels of OJR520 in adults with kidney disease.

Who did this work

Run by Novartis Pharmaceuticals.
Sites: Quotient Sciences Sea View · Novartis Investigative Site

Source

Trial · ClinicalTrials.gov, CKD recruiting · 2026-08-19
https://clinicaltrials.gov/study/NCT07235059